The FDA approved olopatadine hydrochloride/mometasone furoate (Ryaltris) nasal spray, a combination histamine-1(H1)-receptor inhibitor/corticosteroid, for the treatment of symptoms associated with seasonal allergic rhinitis in adults and pediatric patients 12 years of age and older. The safety and effectiveness of olopatadine hydrochloride/mometasone furoate in pediatric patients younger than 12 years of age has not been established.
Olopatadine hydrochloride/mometasone furoate is available in a metered, fixed-dose, aqueous suspension nasal spray. Each unit of the nasal spray contains 665 mcg of olopatadine hydrochloride and 25 mcg of mometasone furoate. The recommended daily dose is two sprays in each nostril twice daily.
In clinical trials, olopatadine hydrochloride/mometasone furoate was associated with a statistically significant improvement in average morning and evening patient-reported 12-hour nasal symptom scores and reflective total ocular symptom scores compared with placebo.
The most common adverse reactions associated with the drug in clinical trials were dysgeusia, epistaxis, and nasal discomfort. Consult product labeling for full prescribing instructions.
